JP2020516659A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516659A5
JP2020516659A5 JP2019555961A JP2019555961A JP2020516659A5 JP 2020516659 A5 JP2020516659 A5 JP 2020516659A5 JP 2019555961 A JP2019555961 A JP 2019555961A JP 2019555961 A JP2019555961 A JP 2019555961A JP 2020516659 A5 JP2020516659 A5 JP 2020516659A5
Authority
JP
Japan
Prior art keywords
alkyl
independently
pharmaceutically acceptable
case
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019555961A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516659A (ja
JP7145874B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/027415 external-priority patent/WO2018191577A1/en
Publication of JP2020516659A publication Critical patent/JP2020516659A/ja
Publication of JP2020516659A5 publication Critical patent/JP2020516659A5/ja
Priority to JP2022148866A priority Critical patent/JP7581294B2/ja
Application granted granted Critical
Publication of JP7145874B2 publication Critical patent/JP7145874B2/ja
Priority to JP2024190472A priority patent/JP7778206B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019555961A 2017-04-14 2018-04-13 ブルトン型チロシンキナーゼの阻害剤としてのベンゾアゼピン類似体 Active JP7145874B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022148866A JP7581294B2 (ja) 2017-04-14 2022-09-20 ブルトン型チロシンキナーゼの阻害剤としてのベンゾアゼピン類似体
JP2024190472A JP7778206B2 (ja) 2017-04-14 2024-10-30 ブルトン型チロシンキナーゼの阻害剤としてのベンゾアゼピン類似体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762485745P 2017-04-14 2017-04-14
US62/485,745 2017-04-14
PCT/US2018/027415 WO2018191577A1 (en) 2017-04-14 2018-04-13 Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022148866A Division JP7581294B2 (ja) 2017-04-14 2022-09-20 ブルトン型チロシンキナーゼの阻害剤としてのベンゾアゼピン類似体

Publications (3)

Publication Number Publication Date
JP2020516659A JP2020516659A (ja) 2020-06-11
JP2020516659A5 true JP2020516659A5 (https=) 2021-05-27
JP7145874B2 JP7145874B2 (ja) 2022-10-03

Family

ID=62092333

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019555961A Active JP7145874B2 (ja) 2017-04-14 2018-04-13 ブルトン型チロシンキナーゼの阻害剤としてのベンゾアゼピン類似体
JP2022148866A Active JP7581294B2 (ja) 2017-04-14 2022-09-20 ブルトン型チロシンキナーゼの阻害剤としてのベンゾアゼピン類似体
JP2024190472A Active JP7778206B2 (ja) 2017-04-14 2024-10-30 ブルトン型チロシンキナーゼの阻害剤としてのベンゾアゼピン類似体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022148866A Active JP7581294B2 (ja) 2017-04-14 2022-09-20 ブルトン型チロシンキナーゼの阻害剤としてのベンゾアゼピン類似体
JP2024190472A Active JP7778206B2 (ja) 2017-04-14 2024-10-30 ブルトン型チロシンキナーゼの阻害剤としてのベンゾアゼピン類似体

Country Status (36)

Country Link
US (5) US10227341B2 (https=)
EP (2) EP4249071A3 (https=)
JP (3) JP7145874B2 (https=)
KR (3) KR102862996B1 (https=)
CN (2) CN110621670B (https=)
AR (2) AR111594A1 (https=)
AU (3) AU2018253209B2 (https=)
CA (1) CA3058774A1 (https=)
CL (1) CL2019002900A1 (https=)
CO (1) CO2019012571A2 (https=)
CR (2) CR20190517A (https=)
DK (1) DK3609886T3 (https=)
EA (1) EA201992354A1 (https=)
ES (1) ES2975769T3 (https=)
FI (1) FI3609886T3 (https=)
HR (1) HRP20240361T1 (https=)
HU (1) HUE066253T2 (https=)
IL (3) IL294175B2 (https=)
JO (1) JOP20190233B1 (https=)
LT (1) LT3609886T (https=)
MA (1) MA50013B1 (https=)
MD (1) MD3609886T2 (https=)
MX (1) MX2023000812A (https=)
PE (2) PE20240930A1 (https=)
PH (1) PH12019502334A1 (https=)
PL (1) PL3609886T3 (https=)
PT (1) PT3609886T (https=)
RS (1) RS65386B1 (https=)
SA (1) SA519410292B1 (https=)
SG (1) SG11201909224QA (https=)
SI (1) SI3609886T1 (https=)
SM (1) SMT202400166T1 (https=)
TW (2) TWI790227B (https=)
UA (1) UA127347C2 (https=)
WO (1) WO2018191577A1 (https=)
ZA (1) ZA202306172B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3080103B9 (en) 2013-12-11 2018-09-19 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
JP7145874B2 (ja) 2017-04-14 2022-10-03 バイオジェン・エムエイ・インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤としてのベンゾアゼピン類似体
EP3866926A1 (en) * 2018-10-15 2021-08-25 Biogen MA Inc. Crystalline polymorphs of bruton's tyrosine kinase inhibitors
WO2020232330A1 (en) * 2019-05-15 2020-11-19 Biogen Ma Inc. Inhibiting agents for bruton's tyrosine kinase
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
US20240216330A1 (en) * 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
EP4429770A1 (en) 2021-11-10 2024-09-18 Biogen MA Inc. Btk inhibitors
AU2022424178A1 (en) 2021-12-30 2024-07-11 Beone Medicines I Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP2125819B1 (en) 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
BRPI0817503B8 (pt) 2007-10-05 2021-05-25 Sstarbio Pte Ltd derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
US20110009421A1 (en) 2008-02-27 2011-01-13 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
PT2473049T (pt) * 2009-09-04 2019-03-04 Sunesis Pharmaceuticals Inc Inibidores de tirosina quinase de bruton
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
BR112014001255B1 (pt) 2011-07-19 2019-07-02 Merck Sharp & Dohme B.V. Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto
TWI648274B (zh) * 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 (二)
WO2014130856A2 (en) 2013-02-21 2014-08-28 Wayne Rothbaum Treatment of skeletal-related disorders
BR112016008632A8 (pt) 2013-10-21 2020-03-17 Merck Patent Gmbh compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
EP3080103B9 (en) 2013-12-11 2018-09-19 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
ES2907622T3 (es) * 2014-10-06 2022-04-25 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de BTK y usos de estos
JP7145874B2 (ja) 2017-04-14 2022-10-03 バイオジェン・エムエイ・インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤としてのベンゾアゼピン類似体

Similar Documents

Publication Publication Date Title
JP2020516659A5 (https=)
DK3024819T3 (en) GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
ES2536191T3 (es) Derivados de sulfonamida
JP6154052B2 (ja) シクロアルカン誘導体の製造方法
JP2018511587A5 (https=)
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
US8822510B2 (en) Substituted 3-phenyl-1,2,4-Oxadiazole compounds
RU2003100516A (ru) Производные сульфонилпирролипидина
RU2011151611A (ru) Композиции для модуляции киназного каскада и способы их применения
JP2003525872A5 (https=)
JP2014532640A5 (https=)
CN102395567A (zh) 在治疗糖尿病和肥胖症中用作的tgr5激动剂的三唑和咪唑衍生物
HRP20240361T1 (hr) Analozi benzoazepina kao sredstva za inhibiciju brutonove tirozin kinaze
RU2006101541A (ru) Производные пиперазина и способ их применения
JP2018503661A5 (https=)
JP2019536810A5 (https=)
HRP20200606T1 (hr) Derivati fenila kao agonisti kanabinoidnog receptora 2
JP2014501232A5 (https=)
JP2004525183A5 (https=)
HRP20150450T1 (hr) Spojevi aril triazola sa antitumorskom aktivnošä†u
AU2008297817A1 (en) 6-pyrimidinyl-pyrimid-4-one derivative
RU2015151742A (ru) Новые производные тетразолона
RU2019103883A (ru) Гетероароматические модуляторы ретинол-связанного орфанного рецептора гамма
JP2019521137A5 (https=)
JP7057427B2 (ja) 寄生虫感染の処置のための新規化合物